期刊
NATURE REVIEWS RHEUMATOLOGY
卷 19, 期 2, 页码 76-77出版社
NATURE PORTFOLIO
DOI: 10.1038/s41584-022-00892-3
关键词
-
类别
Since the start of the SARS-CoV-2 vaccination campaign, our understanding of the effects of vaccines on people with inflammatory rheumatic diseases has been limited. However, three notable papers from the past year have provided key insights and filled these knowledge gaps.
Since the start of the SARS-CoV-2 vaccination campaign, our knowledge of the effects of vaccines in people with inflammatory rheumatic diseases has remained incomplete. In particular, the effects of immunomodulatory therapies on vaccine success are poorly understood. Three notable papers from the past year have helped to fill these knowledge gaps. Key advancesAlthough SARS-CoV-2 vaccination seroconversion rates are lower in individuals with inflammatory rheumatic diseases under immunomodulatory therapy, the neutralizing capacity of anti-SARS-CoV-2 antibodies does not differ between affected and non-affected individuals7.In contrast to the humoral immune response, the cellular immune response to SARS-CoV-2 vaccination in patients receiving rituximab is maintained8.After rituximab therapy, determination of peripheral blood B cells may be a means to facilitate successful immunization, as the threshold for a successful immune response is 10 B cells per microlitre of peripheral blood9.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据